NASDAQ:ALP Portage Biotech (ALP) Stock Price, News & Analysis $5.44 -0.14 (-2.51%) As of 03:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsSEC Filings About Portage Biotech Stock (NASDAQ:ALP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Portage Biotech alerts:Sign Up Key Stats Today's Range$5.25▼$5.5850-Day Range$3.71▼$16.6052-Week Range$3.20▼$690.00Volume40,412 shsAverage Volume227,712 shsMarket Capitalization$8.43 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingReduce Company Overview Portage Biotech Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses. The company’s pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response. As a development-stage biotechnology company, Portage’s products remain subject to clinical testing and regulatory review and are not established commercial therapies. Portage Biotech is incorporated in the British Virgin Islands and has pursued a geographically distributed research and development strategy through collaborations and affiliated biotechnology businesses. Publicly available company information identifies the business as Portage Biotech, Inc.; however, its commonly reported Nasdaq symbol has been PRTG rather than ALP. Leadership and pipeline details may change as the company advances its programs and updates its corporate structure.AI Generated. May Contain Errors. Read More Portage Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreALP MarketRank™: Portage Biotech scored higher than 82% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingReduce Consensus RatingPortage Biotech has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialPortage Biotech has a consensus price target of $12.50, representing about 136.7% upside from its current price of $5.28.Amount of Analyst CoveragePortage Biotech has only been the subject of 3 research reports in the past 90 days.Read more about Portage Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Portage Biotech are expected to grow in the coming year, from ($14.00) to ($8.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Portage Biotech is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Portage Biotech is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.08% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 94.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.82 News SentimentPortage Biotech has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Portage Biotech this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ALP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Portage Biotech in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $235,245.00 in company stock, which represents 2.8745% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $235,245.00 in company stock and sold $0.00 in company stock.Percentage Held by Institutions13.36% of the stock of Portage Biotech is held by institutions.Read more about Portage Biotech's insider trading history. Receive ALP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALP Stock News HeadlinesAlpha Compute Regains Full Compliance with Nasdaq Listing RulesSeptember 25 at 8:00 AM | globenewswire.comPortage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Purchases 10,000 SharesSeptember 24, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 28 at 1:00 AM | Behind the Markets (Ad)Portage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Buys 10,000 Shares of StockSeptember 24, 2026 | insidertrades.comAlpha Compute Signs Binding Contract to Acquire Assets of Operating Oil and Gas Business in PennsylvaniaSeptember 22, 2026 | globenewswire.comPortage Biotech (NASDAQ:ALP) Insider Buys $17,273.25 in StockSeptember 20, 2026 | americanbankingnews.comPortage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Buys 4,265 SharesSeptember 18, 2026 | insidertrades.comPortage Biotech (NASDAQ:ALP) Insider Acquires 7,000 Shares of StockSeptember 15, 2026 | insidertrades.comSee More Headlines ALP Stock Analysis - Frequently Asked Questions How have ALP shares performed this year? Portage Biotech's stock was trading at $38.27 at the beginning of 2026. Since then, ALP shares have decreased by 86.2% and is now trading at $5.28. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:ALP) released its quarterly earnings data on Thursday, July, 16th. The company reported $23.75 earnings per share (EPS) for the quarter. The business had revenue of $0.05 million for the quarter. When did Portage Biotech's stock split? Shares of Portage Biotech reverse split on Wednesday, September 9th 2026.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Portage Biotech? Shares of ALP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/16/2026Today9/28/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ALP's financial health is in the Yellow zone, according to TradeSmith. ALP has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry IT Services Sub-IndustryInternet Services & Infrastructure Current SymbolNASDAQ:ALP Previous SymbolNASDAQ:ATON CIK1095435 Webportagebiotech.com Phone(416) 737-7600FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Price Target for Portage Biotech$12.50 High Price Target$12.50 Low Price Target$12.50 Potential Upside/Downside+133.2%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio0.31 Quick Ratio0.31 Sales & Book Value Annual Sales$100 thousand Price / Sales83.08 Cash FlowN/A Price / Cash FlowN/A Book Value$13.90 per share Price / Book0.39Miscellaneous Outstanding Shares1,550,000Free FloatN/AMarket Cap$8.31 million OptionableN/A Beta0.54 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ALP) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our Partners"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.